Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep/Oct;14(5):e257-e260.
doi: 10.1097/ADM.0000000000000718.

Early Effects of COVID-19 on Programs Providing Medications for Opioid Use Disorder in Jails and Prisons

Sachini Bandara  1 , Alene Kennedy-Hendricks, Sydney Merritt, Colleen L Barry, Brendan Saloner
Affiliations

Early Effects of COVID-19 on Programs Providing Medications for Opioid Use Disorder in Jails and Prisons

Sachini Bandara et al. J Addict Med. 2020 Sep/Oct.

Abstract

Objectives: To describe how the novel coronavirus (COVID-19) pandemic has affected opioid agonist treatment (OAT) programs in jails and prisons.

Methods: In May 2020, we conducted an online survey of 19 carceral systems that provided methadone and/or buprenorphine treatment for incarcerated populations before COVID-19. Eleven survey items examined challenges and changes to these programs as a result of the pandemic. Sixteen of 19 programs (84%) responded to the survey.

Results: Ten out of 16 systems reported downsizing their OAT programs. Seven of 16 systems made changes to medication dispensation processes. Half of systems report challenges implementing physical distancing (n = 8), and/or obtaining personal protective equipment (n = 8). In 13 out of 16 systems some OAT program participants were released early due to COVID-19 infection risk.

Conclusions: Jails and prisons with existing OAT programs have curtailed their operations in the context of the COVID-19 pandemic. Given the robust evidence base around OAT for treating opioid use disorder and averting overdose deaths, guidance is needed on maintaining and ramping up medication access as carceral facilities grapple with implementing COVID-19 mitigation.

PubMed Disclaimer

References

    1. Wallace M, Hagan L, Curran KG, et al. COVID-19 in correctional and detention facilities — United States, February–April 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (19):587–590.
    1. Akiyama MJ, Spaulding AC, Rich JD. Flattening the curve for incarcerated populations — Covid-19 in jails and prisons. N Engl J Med 2020; 382 (22):2075–2077. NEJM2005687.
    1. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. Medications for Opioid Use Disorder Save Lives. (Mancher M, Leshner AI, eds.). National Academies Press (US); 2019.Available at: http://www.ncbi.nlm.nih.gov/books/NBK538936/. Accessed May 14, 2020.
    1. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison — a high risk of death for former inmates. N Engl J Med 2007; 356 (2):157–165.
    1. LaBelle R, Weizman S. Applying. The Evidence: Legal and Policy Strategies to Address Opioid Use Disorder in Criminal Justice And Child Welfare Systems. O’Neill Institute for National and Global Health Law at Georgetown Law Center; 2019. Available at:https://oneill.law.georgetown.edu/wp-content/uploads/Applying-the-Eviden.... Accessed May 22, 2019.

Publication types

Substances

LinkOut - more resources